GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • WASHINGTON, April 18- U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.

  • Court declines to block drug ruling in patent case Friday, 18 Apr 2014 | 4:08 PM ET

    WASHINGTON— Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month. Teva claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug.

  • WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • Teva willing to post $500 million bond in Copaxone case Thursday, 17 Apr 2014 | 3:18 PM ET

    WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • April 17- Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. "helps them to get through 2014 with a lot less competition," Morningstar analyst Damien Conover said.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent litigation with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster pain medication, Celebrex, in December. Celebrex's basic chemical patent expires on May 30.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

  • Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Ltd asked the U.S. Supreme Court on Monday to stop a lower court ruling from going into effect while the justices consider an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

  • March 31- Eli Lilly was successful in a crucial legal battle on Monday when a U.S. The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the' 209 Patent are invalid.

  • WASHINGTON, March 31- The U.S. Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone, a move that could deter generic manufacturers from introducing cheaper versions onto the market as soon as May.

  • U.S. justices agree to hear Teva's Copaxone appeal Monday, 31 Mar 2014 | 9:36 AM ET

    By agreeing to hear the case, the high court cast into doubt a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd. The appeals court upheld some of nine patents involved in the drug, or portions thereof, but declared several invalid, meaning patent protections were set to expire in May 2014 instead of September 2015.

  • Your first trade for Friday Thursday, 27 Mar 2014 | 3:41 PM ET

    The "Fast Money" traders share their final trades of the day.

  • In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries Ltd, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India, they said.

  • WASHINGTON, March 24- The U.S. Supreme Court on Monday for the second time did not announce whether it would hear an appeal by Teva Pharmaceutical Industries Ltd in a patent fight with generic competitors over a top-selling multiple sclerosis drug.

  • U.S. top court takes no action in Teva MS drug case Monday, 24 Mar 2014 | 10:42 AM ET

    WASHINGTON, March 24- The U.S. Supreme Court on Monday for the second time did not announce whether it would hear an appeal by Teva Pharmaceutical Industries Ltd in a patent fight with generic competitors over a top-selling multiple sclerosis drug.

  • Your first trade for Monday Friday, 14 Mar 2014 | 1:15 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Midday movers: Castlight Health, Coach, Ann & More Friday, 14 Mar 2014 | 12:11 PM ET

    Some of Friday's midday movers:

Most Popular Video

Thursday, 24 Apr 2014 | 1:05 AM ET

Jerry Braakman, chief investment officer at First American Trust, says Apple and Facebook reported "great" results and owning technology stocks is still attractive.

Thursday, 24 Apr 2014 | 12:16 AM ET

Manpreet Gill, Senior Investment Strategist at Standard Chartered Bank, attributes the decline of Japanese shares to the lack of a TPP agreement during U.S. President Barack Obama's visit to Tokyo.

Wednesday, 23 Apr 2014 | 3:00 PM ET

CNBC's Becky Quick discusses Warren Buffett's feelings about Coke, IBM and his general sentiment about the market.